Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02566's EV-to-FCF is ranked better than 68.5% of 327
companies
in the Biotechnology industry
Industry Median: 18.51
vs HKSE:02566: 3.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's share price for today is HK$5.41.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.614.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co EV-to-FCF Related Terms
Hangzhou Jiuyuan Genetic Biopharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co EV-to-FCF Chart
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
EV-to-FCF
0.00
0.00
0.00
68.72
7.50
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Semi-Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co EV-to-FCF vs Biotechnology Industry
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Enterprise Value is HK$657 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$166 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a EV-to-FCF of 3.95 as of Aug. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors. This is 91% below median its historical median of 44.38. Over the past decade, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's EV-to-FCF has ranged from 3.82 to 161.70. According to the industry distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #103 out of 327 companies in the Biotechnology industry, placing it in the top 31.5%.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co's EV-to-FCF too high?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current EV-to-FCF of 3.95 is 91% below median its 10-year median of 44.38. Over the past 10 years, this metric has ranged from a low of 3.82 to a high of 161.70. The Biotechnology industry median EV-to-FCF is 18.51. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's value of 3.95 is 78.7% below this industry median. Based on the distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #103 out of 327 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hangzhou Jiuyuan Genetic Biopharmaceutical Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Jiuyuan Genetic Biopharmaceutical Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #103 out of 327 companies for EV-to-FCF. This puts Hangzhou Jiuyuan Genetic Biopharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 18.51. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's value of 3.95 is 78.7% below this benchmark. Historically, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's own EV-to-FCF has ranged from 3.82 to 161.70 over the past decade. While the company's 10-year median is 44.38 vs. the industry median of 18.51, Hangzhou Jiuyuan Genetic Biopharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 18.51, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current EV-to-FCF of 3.95 is 78.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 18.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current EV-to-FCF is 3.95, which is 91% below median its own 10-year median of 44.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co stock overvalued right now?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a current EV-to-FCF of 3.95. The current EV-to-FCF is 3.95, which is 91% below median its 10-year median of 44.38 and 78.7% below the Biotechnology industry median of 18.51. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566), the current EV-to-FCF is 3.95 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, it has built a diversified product portfolio comprising several marketed products, such as Jilifen, Jijufen, Jiouting, Yinuojia, Guyoudao, etc., and has several product candidates under development, such as JY54, JY23, JY47, JY56, JY29-2, etc., targeting various indications. Geographically, the company generates maximum revenue from the Chinese Mainland, and the rest from other countries.
20GF Score
Get the complete analysis for HKSE:02566
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02566 has been successfully added to your 
